Author: administrator

Sales of Rhizoma Gastrodiae Tablets for Online Pharmacies Is Likely to Expand at under 5% CAGR until 2031

Post author By administrator
Post date October 17, 2021
No Comments on Sales of Rhizoma Gastrodiae Tablets for Online Pharmacies Is Likely to Expand at under 5% CAGR until 2031

According to a recently published report by award-winning consulting firm Fact.MR. Heavy emphasis on herbal-based and traditional medicines is anticipated to account for bulk of this expansion.The market for rhizoma gastrodiae tablets in the U.S is likely to expand at under 5% CAGR until 2031.

Historically, the market accrued credible gains, expanding at just under 10% CAGR from 2016 to 2020. Prospects have been further heightened amidst the COVID-19 crisis, with several healthcare providers investigating the possibility of incorporating alternative medicine as an effective first-line treatment for severely infected patients.

For more insights into the Market, Request a Sample of this Report https://www.factmr.com/connectus/sample?flag=S&rep_id=6322

As per the World Health Organization, maximum application has been in China, attributed to growing application of Traditional Chinese Medicine (TCM) to treat debilitating diseases such as severe acute respiratory syndrome (SARS). Furthermore, 4 out of 5 healthcare providers in key African countries have embedded alternative medicine as an effective therapy. Moreover, applications have also widened to treat various chronic disorders, including fatty liver.

Key Takeaways from Market Study

Gastrodia elata f. glauca rhizoma gastrodiae tablet demand to expand at an impressive 10% CAGR
By distribution channel, retail pharmacies to account for maximum sales, expanding at a CAGR of approximately 15%
Sales of rhizoma gastrodiae tablets in the U.S. to generate approximately 40% of revenue, expanding at under 5% CAGR
China to remain the epicenter of market growth, yielding over 50% of total revenue
3 out 10 rhizoma gastrodiae tablet sales are expected across India, expanding at a CAGR of 9%
Market in the U.K. to emerge as a promising hub, poised to exhibit a CAGR of approximately 7% through 2031

“Prominent manufacturers of rhizoma gastrodiae tablets are likely to majorly incline towards key emerging economies across Asia and Africa, amid heightened scope of traditional medicine in key countries,” concludes a Fact.MR analyst.

Get Customization on this Research Report for specific research solutions https://www.factmr.com/connectus/sample?flag=RC&rep_id=6322

rhizoma gastrodiae tablets market

Key Market Segments Covered

Type
- Gastrodia Elata F. Glauca Rhizoma Gastrodiae Tablets
- G. Elata Bl. F. Elta Rhizoma Gastrodiae Tablets
- Other Rhizoma Gastrodiae Tablets
Distribution Channel
- Rhizoma Gastrodiae Tablets for Hospital Pharmacies
- Rhizoma Gastrodiae Tablets for Retail Pharmacies
- Rhizoma Gastrodiae Tablets for Online Pharmacies
Region
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Spain
  - Italy
  - Rest of Europe
- East Asia
  - China
  - Japan
  - South Korea
  - Rest of East Asia
- South Asia
  - India
  - ASEAN
  - Rest of South Asia
- Middle East & Africa
  - GCC
  - South Africa
  - Rest of MEA
- Oceania
  - Australia & New Zealand
  - Rest of Oceania

Full Access of this Report Is Available at https://www.factmr.com/checkout/6322

Competitive Landscape

Prominent rhizome gastrodiae tablet manufacturers as profiled in Fact.MR’s report include Zhaotong Huacheng Pharmaceuticals, Guangdong Luofu Shan National Pharmaceutical Co. Ltd., Beijing Tong Ren Tang, Guizhou Bailing Group,Guangxi Changzhou Natural Pharmaceutical Co. Ltd., Lanzhou Foci Pharmaceutical, Shaanxi Tianyang Pharmaceutical, Taiji Group Sichuan Mianyang Pharmaceutical,and Tsumura & Co.

In June 2017, Beijing Tong Ren Tang Europe Holding B.V entered a strategic co-operation agreement with the Republic of Kazakhstan for establishing a Chinese Medical Center to further Chinese Medicine.
In November 2019, Tsumura & Co. concluded its Letter of Intent regarding Tianjin China Medico Technology Co. Ltd. to forge a capital alliance with the intention of expanding its business in Traditional Chinese Medicine and ensure stable supply of crude drugs.

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the rhizoma gastrodiae tablets market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of type (Gastrodia Elata F. Glauca, G. Elata Bl. F. Elata, and others) and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), across seven major regions of the world (North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa).

For More Insights https://www.biospace.com/article/acquired-cystic-kidney-disease-treatment-demand-fuelled-by-increased-r-and-d-activities-says-fact-mr/

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Tags Demand for Rhizoma Gastrodiae Tablets, G. Elata Bl. F. Elta Rhizoma Gastrodiae Tablets, gastrodia elata f. glauca rhizoma gastrodiae tablets, Global Rhizoma Gastrodiae Tablets Market, rhizoma gastrodiae tablets, Rhizoma Gastrodiae Tablets for Hospital Pharmacies, Rhizoma Gastrodiae Tablets for Online Pharmacies, Rhizoma Gastrodiae Tablets for Retail Pharmacies, Rhizoma Gastrodiae Tablets Market, sales of rhizoma gastrodiae tablets, types of rhizoma gastrodiae tablets

Pharmaceutical

How are Single Donor Human Umbilical Vein Endothelial Cells (HUVEC) Generating Demand : Fact.MR

Post author By administrator
Post date October 17, 2021
No Comments on How are Single Donor Human Umbilical Vein Endothelial Cells (HUVEC) Generating Demand : Fact.MR

Award-winning consulting firm Fact.MR’s report on the global human umbilical vein endothelial cells (HUVEC) market forecasts a healthy growth trajectory for the 2021-2031 forecast period. According to the study, rapid advancements in biotechnology and genetic engineering are opening up new growth avenues for advanced disease treatment, particularly across areas such as oncology. Demand for human umbilical vein endothelial cell-based treatment has been gradually gaining momentum, as advancements in genetic engineering and biotechnology become increasingly overt.

As per data published by GLOBOCAN, global cancer burden rose to 19.3 million cases, while associated fatalities increased to 10 million by 2020. Amongst all the cancers, breast cancer accounts for nearly a quarter of the total cases diagnosed every year. Hence, healthcare providers are incorporating highly advanced therapeutic approaches, thereby widening the growth prospects for human umbilical vein endothelial cells.

For more insights into the Market, Request a Sample of this Report https://www.factmr.com/connectus/sample?flag=S&rep_id=6216

Manufacturers are directing bulk of their investments across key regions such as China, India, and other countries in Asia Pacific. Over the years, these countries have witnessed unprecedented expansion of their existing healthcare infrastructure. This is majorly attributed to the presence of a huge population base, necessitating delivery of advanced healthcare for various chronic and infectious diseases.

Key Takeaways from Market Study

By type, pooled donor-derived HUVECs are expected to experience elevated sales through 2031
Oncology to emerge as a highly promising application area for HUVEC-based treatment
The U.S. to generate multiple revenue streams for the market, across CVD treatment, oncology, and angiogenesis
Extensive development of biotechnology and cell culture studies driving demand across India

“Rapid advancements in healthcare are prompting developments across key therapeutic areas, providing enough room for the proliferation of HUVEC-based therapeutics,”remarks a Fact.MR analyst.

Get Customization on this Research Report for specific research solutions https://www.factmr.com/connectus/sample?flag=RC&rep_id=6216

human umbilical vein endothelial cells huvec market

Key Market Segments Covered

Type
- Single Donors of Human Umbilical Vein Endothelial Cells
- Pooled Donors of Human Umbilical Vein Endothelial Cells
Application
- Human Umbilical Vein Endothelial Cells for Wound Healing
- Human Umbilical Vein Endothelial Cells for Angiogenesis
- Human Umbilical Vein Endothelial Cells for Tissue Engineering
- Human Umbilical Vein Endothelial Cells for Inflammation Treatment
- Human Umbilical Vein Endothelial Cells for Oncology
- Human Umbilical Vein Endothelial Cells for Other Applications
Region
- North America
  - U.S.
  - Canada
- Europe
  - Germany
  - France
  - U.K
  - Italy
  - Russia
  - Nordics
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - South Korea
  - India
  - Australia
  - Rest of Asia Pacific
- Latin America
  - Mexico
  - Brazil
  - Rest of Latin America
- Middle East & Africa
  - GCC
  - Turkey
  - Rest of MEA

Full Access of this Report Is Available at https://www.factmr.com/checkout/6216

Competitive Landscape

Prominent HUVEC providers as profiled by Fact.MR include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc. Due to the presence of such a handful of service providers, the market appears highly consolidated.

In May 2021, Merck & Co. announced 40 abstracts, seven oral presentations and seven poster discussions from company and investigator sponsored studies and external collaborations for its oncology treatment furtherance, an initiative which will likely provide tailwinds to its HUVEC portfolio.
In January 2021, PromoCell received the EXCiPACTTM certification scheme for pharmaceutical excipients to Good Manufacturing Practice (GMP) standards, which implied that the company can provide tailor-made cell culture media and reagents based on each client’s end user requirements.

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the human umbilical vein endothelial cells market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of type (single donors and pooled donors) and application (wound healing, angiogenesis, tissue engineering, inflammation, oncology, and others), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

For More Insights https://www.biospace.com/article/cell-proliferation-market-players-are-relying-on-partnerships-and-alliance-to-speed-up-r-and-d-study/

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Tags cryopreserved HUVECs, demand of pooled donor HUVECs, global human umbilical vein endothelial cells (HUVEC) market, global human umbilical vein endothelial cells market, human umbilical vein endothelial cells (HUVEC) market, human umbilical vein endothelial cells market, HUVEC-based treatment, HUVECs for oncology, pooled donors of human umbilical vein endothelial cells, single donors of human umbilical vein endothelial cells

Pharmaceutical

Demand for Nizatidine Tablets are Expected to Witness Credible Upsurge at Over 10% CAGR: Report Fact.MR

Post author By administrator
Post date October 17, 2021
No Comments on Demand for Nizatidine Tablets are Expected to Witness Credible Upsurge at Over 10% CAGR: Report Fact.MR

Award-winning consulting firm Fact.MR’s recently published report on the global nizatidine market for the forecast period 2021-2031 expects an optimistic future outlook, projecting noteworthy growth for the said period. Growth is expected to be primarily fueled by extensive application in gastric disorder treatment. sales of nizatidine capsules are expected to witness credible upsurge at over 10% CAGR, attributed to their ease of swallowing and presence of low odor and pleasant taste.

According to a study published by a group of researchers at the University of Gothenburg, nearly 40% of adults suffer from a functional gastrointestinal disorder in a 73,000 person, 33 country survey. Functional gastrointestinal disorders represent a series of chronic disorders in the gastrointestinal tract that often include severe symptoms such as heartburn, acid reflux, and dyspepsia in the upper gastrointestinal tract.

For more insights into the Market, Request a Sample of this Report https://www.factmr.com/connectus/sample?flag=S&rep_id=6217

The market experienced hiccups in the recent past amid a series of product recalls by prominent manufacturers due to several compliance incompatibilities. However, these withdrawals have been overturned, reopening growth frontiers. For instance, in September 2020, Amneal Pharmaceuticals Inc. announced that its nizatidine oral solution 15 mg/ml was available for reorder across the U.S., meeting all FDA requirements.

Key Takeaways from Market Study

By type, nizatidine capsules of doses of 150 mg and 300 mg to remain most preferred
Retail and online sales of nizatidine products to experience massive incline over coming years
Resumption of regulatory approval grants to stimulate nizatidine sales across the U.S.
India to attract significant investments, attributed to high domestic manufacturing capabilities of generic drugs
China to generate high demand amid rising prevalence of gastric cancer and irritable bowel syndrome

“Surging healthcare costs associated with availing high-grade gastrointestinal disorder treatment are prompting a shift towards consuming orally administered nizatidine capsules and tablets,”says a Fact.MR analyst.

Get Customization on this Research Report for specific research solutions https://www.factmr.com/connectus/sample?flag=RC&rep_id=6217

Key Market Segments Covered

Type
- Nizatidine Capsules
- Nizatidine Tablets
- Other Nizatidine Types
Application
- Nizatidine for Hospital Pharmacies
- Nizatidine for Retail Pharmacies
- Nizatidine for Online Pharmacies
Region
- North America
  - U.S.
  - Canada
- Europe
  - Germany
  - U.K
  - France
  - Spain
  - Italy
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - Southeast Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Mexico
  - Rest of Latin America
- Middle East & Africa
  - GCC
  - South Africa
  - Rest of MEA

Full Access of this Report Is Available at https://www.factmr.com/checkout/6217

Competitive Landscape

Major players in the market that are associated with offering nizatidine-based formulations and nizatidine, in itself, include Flynn Pharma, MedChemExpress, Mylan N.V., Glenmark Pharmaceuticals, Weightech (Hunan) Pharmaceutical, Hengdian Group, Dr. Reddy’s Laboratories, Eli Lily and Company, and Strides Pharma Science Limited.

These aforementioned players largely concentrate on offering different formulations of nizatidine so as to especially cater to gastrointestinal ailments. A majority of these players are scrambling to acquire regulatory approvals from appropriate authorities to secure a firm footing in the market across regions and increased their revenue and profit margins.

For More Insights https://www.biospace.com/article/polycystic-kidney-disease-treatment-demand-fuelled-by-rising-instances-of-adpkd-across-the-world-says-fact-mr/

More Insights on the Nizatidine Market

Fact.MR, in its new offering, presents an unbiased analysis of the nizatidine treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of type (capsules, tablets, and others) and application (hospital pharmacies, retail pharmacies, and online pharmacies) across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The report provides qualitative and quantitative information on various players in this market. This report also tracks the market by both, supply side and demand side trends.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Tags Demand for Nizatidine, Demand for Nizatidine Tablets, Global Nizatidine Market, Nizatidine Manufacturers, Nizatidine Market, Nizatidine Market Growth, Nizatidine Market Size, Nizatidine Market Trends, Sales of Nizatidine, Sales of Nizatidine Capsules

Pharmaceutical

Demand for Rare Neurodegenerative Disease Treatment Market to Reach US$ 116 Bn by 2030

Post author By administrator
Post date October 15, 2021
No Comments on Demand for Rare Neurodegenerative Disease Treatment Market to Reach US$ 116 Bn by 2030

The global rare neurodegenerative disease treatment market is projected to witness steady growth at a CAGR of 5%, reaching a valuation of over US$ 116 billion by 2030. However, the coronavirus outbreak is expected to have a marginally negative impact on the industry in the short term. Supply chain issues and dedication of healthcare facilities towards handling the unprecedented challenges of the pandemic are hindering market growth at present.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=5197

On the other hand, increasing investments by market players towards drug development for the treatment of neurodegenerative diseases, and rising awareness among patients about varied treatment options, are major contributors to the growth of the market. Also, rise in medical tourism and investments towards modernization of healthcare infrastructure across developing countries in Asia Pacific are expected to benefit the rare neurodegenerative disease treatment market in the long term.

Key Takeaways from Rare Neurodegenerative Disease Treatment Market Study

North America is a prominent regional market, accounting for a major market share on the back of high healthcare expenditure and the presence of top pharmaceutical manufacturers in the region.
Hospital pharmacies are the leading channel of distribution for drugs associated with neurodegenerative diseases, driven by larger inventories.
Multiple sclerosis is the leading indication in the rare neurodegenerative disease treatment market, supported by growing awareness about the disease and rise in cases in recent years.
Sales of neuroprotective agents are essential for market revenue, with popularity supported by reduced side effects.
The COVID-19 pandemic is expected to have a moderate adverse impact on the global rare neurodegenerative disease treatment market in the short term.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=5197

“Lack of awareness about neurodegenerative disease treatments among populations in rural and developing regions and dearth of curative treatment options as compared to disease management offerings are challenges that players in the market will have to contend with,” says a Fact.MR analyst.

Key Segments of Rare Neurodegenerative Disease Treatment Market

Fact.MR’s study on the rare neurodegenerative disease treatment market offers information divided into four important segments — indication, drug class, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Indication	Drug Class	Distribution Channel	Region
Multiple Sclerosis Alzheimer’s Disease Parkinson’s Disease Acute Migraine Autism Narcolepsy Amyotrophic Lateral Sclerosis (ALS) Attention Deficit Hyperactivity Disorder (ADHD) Spinal Muscular Atrophy Tourette Syndrome Huntington’s Disease Others	Neurotransmitter Agents Neuroprotective Agents Biologics Others	Hospital Pharmacies Online Pharmacies Retail Pharmacies	North America Latin America Europe Asia Pacific Middle East & Africa

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/5197

Research on Product Development – Key to Market Growth

Leading players in the global rare neurodegenerative disease treatment market, such as Allergan plc, Bayer AG, GlaxoSmithKline, Johnson & Jonson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. are increasingly investing in capacity and geographical expansion and research into product development pertaining to neurodegenerative ailments. These are key factors that are likely to contribute to the growth of revenue and bolster product improvement in the competitive rare neurodegenerative disease treatment market landscape in the long term.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

ENT Cameras Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2281/ent-cameras-market

Automated Dialysis Concentrated Production Systems Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2280/automated-dialysis-concentrated-production-systems-market

Oral & Topical Anaesthetics Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2279/oral-topical-anaesthetics-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Tags Rare Neurodegenerative Disease Treatment Market, Rare Neurodegenerative Disease Treatment Market Analysis, Rare Neurodegenerative Disease Treatment Market Demand, Rare Neurodegenerative Disease Treatment Market Estimate, Rare Neurodegenerative Disease Treatment Market Forecast, Rare Neurodegenerative Disease Treatment Market Insights, Rare Neurodegenerative Disease Treatment Market Scope, Rare Neurodegenerative Disease Treatment Market Share, Rare Neurodegenerative Disease Treatment Market Size, Rare Neurodegenerative Disease Treatment Market Statistics, Rare Neurodegenerative Disease Treatment Market Trends

Pharmaceutical

Demand for Medical Gases and Equipment Market to Grow at Over 8% CAGR Through 2030

Post author By administrator
Post date October 15, 2021
No Comments on Demand for Medical Gases and Equipment Market to Grow at Over 8% CAGR Through 2030

The global medical gases and equipment market is exhibiting steady growth with the surge in demand from hospitals, home care settings, pharmaceutical companies, and other healthcare facilities. A recent study by Fact.MR states that the medical gases and equipment market is anticipated to grow at over 8% CAGR during the forecast period between 2020 and 2030.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=5428

Rising cases of chronic ailments such as diabetes, cancer, asthma, cardiovascular and respiratory diseases, and communicable diseases have been creating scope for expansion. According to the Centers for Disease Control and Prevention, one out of two adults in the U.S. suffer from chronic diseases.

Data obtained from same source revealed that 86% of national expenditure, accounting for US$ 2.7 trillion, were incurred on the treatment of mental health conditions and chronic ailments in the U.S. These facts and figures indicate the surge in incidence of chronic ailments, which is expected to fuel the demand for medical gases and equipment in the coming years.

Though the outbreak of COVID-19 pandemic has impacted production process across manufacturing units in the first half of this year, the market is forecast to recover soon owing to the rush of patients across healthcare facilities.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=5428

Key Takeaways from Medical Gases and Equipment Market Report

The increase in therapeutic application of medical gases and equipment is forecast to fuel the sales through the forecast period
Hospitals will continue exhibiting surging demand in the coming years
North America will dominate in the global medical gases and equipment market, with the U.S at the forefront. The demand from East Asia too is expected to rise in the coming years
With the on-set of COVID-19 pandemic, the market has been experiencing surge in demand which tends to persist over the next couple of years

Medical Gases and Equipment Market – Segmentation

Application

Therapeutic
Pharmaceutical Manufacturing & Research
Diagnostic
Other Applications

End User

Hospitals
Home Care Settings
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Emergency Services

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/5428

Some of the companies profiled in the medical gases and equipment market report are Airgas Inc., Atlas Copco AB, GCE Group AB, Matheson Tri-Gas Inc., Messer Group GmbH, and Praxair Inc.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Percussion Vests Market Forecast, Trend Analysis, & Competition Tracking – Global Review 2020 to 2030- https://www.factmr.com/report/5263/percussion-vests-market

Continuous Cardiac Monitoring Systems Market Forecast, Trend Analysis, & Competition Tracking – Global Review 2020 to 2030- https://www.factmr.com/report/5265/continuous-cardiac-monitoring-systems-market

Handheld Fluorescence Imaging Devices Market Forecast, Trend Analysis, & Competition Tracking – Global Review 2020 to 2030 – https://www.factmr.com/report/5266/handheld-fluorescence-imaging-devices-market

About Us:

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Tags Medical Gases and Equipment Market, Medical Gases and Equipment Market Analysis, Medical Gases and Equipment Market Demand, Medical Gases and Equipment Market Estimate, Medical Gases and Equipment Market forecast, Medical Gases and Equipment Market insights, Medical Gases and Equipment Market Scope, Medical Gases and Equipment Market Share, Medical Gases and Equipment Market size, Medical Gases and Equipment Market Statistics, Medical Gases and Equipment Market Trends

Pharmaceutical

Global Microscopy Devices Market to Grow at a CAGR of 8.5% Through 2025

Post author By administrator
Post date October 15, 2021
No Comments on Global Microscopy Devices Market to Grow at a CAGR of 8.5% Through 2025

The usage of microscopy devices has registered an uptick in the past few years. Microscopes have allowed in-depth academic and exploratory research in various branches of science. Amongst the wide range of sciences, the life sciences division has found increased usage of microscopy devices, particularly in cell biology. Also, the need for more penetrative media to identify cells has boosted technological developments in microscopic devices. On the back of these trends, the global microscopy devices market is poised to expand 1.6x, registering a CAGR of 8.5% throughout the forecast period (2020-2025).

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4796

Nowadays, major life science companies are increasingly seeking the services of contract research organizations (CROs) to reduce their overall expenditure and concentrate on their core businesses. This has enabled several microscopy service providers to invest in research and development of microscopes. The ongoing coronavirus pandemic is anticipated to leverage market prospects. With the number of infections climbing at an exponential rate, hospitals and other healthcare settings have experienced an uptick in the number of diagnostic tests to determine the presence of the virus. On the back of this, the usage of microscopes to detect potential pathogens has increased. Leading players are therefore concentrating on streamlining their production processes to cater to this increased demand.

Key Takeaways of Global Microscopy Devices Market Study:

Optical microscopes are projected to account for a major chunk of the market, capturing more than three-fifths of the market share. Rising demand for different types of optical microscopes such as fluorescence and inverted microscopes and low cost of stereo and phase contrast microscopes shall drive the segment’s growth.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=4796

By application, Cell and Molecular Biology and Biomedical engineering are anticipated to make exhaustive utilization of microscopy devices. This is due to increased adoption of microscopes in microbiology, cell culture, healthcare monitoring and launch of new therapeutic products. Projected CAGR for both segments is pegged at 8.3%.
Clinical Pathology and Diagnostics shall find equally important microscopy applications, for understanding pathological changes in conditions such as Alzheimer’s and Parkinson’s diseases and chronic diseases. Anticipated CAGR for this segment is a staggering 8.2%.
By end-users, diagnostic laboratories are anticipated to find maximum usage of microscopy devices. The need to accurately identify potentially life-threatening diseases such as tuberculosis and immunological ailments such as HIV-AIDS and diabetes in order to suggest appropriate corrective course of action is anticipated to drive the segment’s growth.
Asia-Pacific is projected to emerge as the leader of the global microscopy devices market, capturing more than half of the total market share. An emerging pharmaceutical industry, liberalization and deregulation of key markets and rising adoption of electron and scanning probe microscopes shall drive the Asia-Pacific regional growth.
However, North America is projected to soar in popularity due to increased patent filing approvals, increased government funding for life sciences projects, greater flexibility in regulations and high transparency. Besides, adoption of optical microscopes is poised to increase during the forecast period. The region is set to expand 1.6x, capturing nearly one-fourth of the global microscopy devices market.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4796

“The global microscopy devices market is poised to experience a healthy growth trajectory. Rising incentives for research in life sciences in the form of government funding, relaxation of regulations and growing healthcare infrastructure are anticipated to leverage the prospects of microscopy devices,” concludes a Fact.MR analyst.

Technological Developments to Boost Key Players’ Market Prospects:

The global microscopy devices market consists of the following key market players: Olympus Corporation, JOEL Ltd., Nikon Corporation, Carl Zeiss Microscopy GmBh, FEI Company, Leica Microsystems, Hitachi High-Technologies Corporation, Bruker Corporation and CAMECA SAS. Most of these market players rely on technological advancements to increase market presence.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

ENT Cameras Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2281/ent-cameras-market

Oral & Topical Anaesthetics Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2279/oral-topical-anaesthetics-market

About Us:

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Tags Microscopy Devices Market, Microscopy Devices Market Analysis, Microscopy Devices Market Demand, Microscopy Devices Market Estimate, Microscopy Devices Market Forecast, Microscopy Devices Market Insights, Microscopy Devices Market Scope, Microscopy Devices Market Share, Microscopy Devices Market Size, Microscopy Devices Market Statistics, Microscopy Devices Market Trends

Pharmaceutical

What are Key Growth Influencers of the Controlled Substances Market

Post author By administrator
Post date October 15, 2021
No Comments on What are Key Growth Influencers of the Controlled Substances Market

Worldwide sales of the controlled substances closed in on a valuation of US$ 67,000 Mn in 2018, and are projected to record a Y-o-Y growth at 3.5% in 2019, according to a new Fact.MR study. The study opines that depressants and stimulants have been top-selling class of drugs in the controlled substances market, however gains from marijuana are expected to record over 2X faster growth than all the other controlled substances in 2019 and beyond.

Approval of medical marijuana has been on a significant uptick in various states of the US, trailed by the legalization in Canada for both recreational and medicinal use recently. This has tremendously contributed to the popularity of cannabis stocks, alongside efforts of leading controlled substance manufacturers toward eliminating legal barriers and attracting investor interest. The study estimates marijuana sales in 2019 to record a Y-o-Y growth at 9.3% over 2018.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=2032

“The Schedule of Controlled Substances currently positions marijuana in Schedule 1 – the most restrictive one reserved for “high potential for abuse,” “lack of accepted safety” and “no accepted medical use” drugs. Federal scheduling of marijuana has been a key concern among producers and medical patients alike, despite legalization of cannabis in the US and Canada. The US Drug Enforcement Administration has recently removed cannabidiol from Schedule 1, post-FDA approval of non-synthetic, cannabis-derived medicine. Marijuana businesses have cheered the DEA’s action, as it alludes the beginning of regulatory relaxation to the cannabis industry,” according to a lead analyst at Fact.MR.

Pain Management Remains Leading Application of Controlled Substances

The study opines that pain management will continue to account for over one-fourth share of the controlled substances market in 2018. Several regulatory norms being implemented in the prescription of controlled substances for pain management, such as in Georgia, Michigan, and Florida, have further triggered the preference and adoption of controlled substances to manage and treat chronic as well as acute pain. Attention deficit hyperactivity disorder (ADHD), and anxiety are other medical conditions wherein controlled substances are expected to witness promising future prospects, according to the study.

For critical insights on this market, request for methodology here https://www.factmr.com/connectus/sample?flag=RM&rep_id=2032

The entrance of pharmaceutical giants in the cannabis sector of Canada alludes the next significant trend in the controlled substances industry, offering additional credibility to the sector. Although the pharmaceutical part of the expression involves the missing link, an ongoing trend of M&A and entrance of these legacy industries is poised in 2019 and the foreseeable future. There has been a drought in direct investments from the pharmaceutical industries in the licensed medical marijuana producers, it is highly likely that the trend would change, as the US witnesses the federal legalization of cannabis. Big pharmaceutical companies that eye collaborations and partnerships with cannabis producers having competitive differentiation circling their R&D initiatives, commercialization efforts, and clinical trial programs, are likely to witness significant revenue generation in the near future.

Ensuring effective and safe management of controlled drugs continues to remain an imperative agenda among pharmacists, which in turn has led the focus on fundamental changes including reviewing of liquid CD management and CD documentation to realize substantial improvements. The pharmacists are also adhering to the operational standards, completely aware about the way CDs are managed, along with identifying potential drawbacks and reporting concerns regarding non-conformance. This will result in adherence to appropriate steps that ensure apt prescription of quantities when dispensing controlled substances to patients.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/2032

This Fact.MR report also offers an accurate forecast of the controlled substances market for the period between 2018 and 2028. The controlled substances market is envisaged to record a CAGR of 4% through 2028

About Us:

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Tags Controlled Substances Market, Controlled Substances Market Analysis, Controlled Substances Market Demand, Controlled Substances Market Estimate, Controlled Substances Market Forecast, Controlled Substances Market Insights, Controlled Substances Market Scope, Controlled Substances Market Share, Controlled Substances Market Size, Controlled Substances Market Statistics, Controlled Substances Market Trends

Pharmaceutical

What is the Role of Advanced R&D in Widening Lithotripsy Devices Demand

Post author By administrator
Post date October 15, 2021
No Comments on What is the Role of Advanced R&D in Widening Lithotripsy Devices Demand

The lithotripsy devices market is projected to continue its steady growth due to the burgeoning cases of kidney stones, coupled with the surging demand for minimally invasive medical treatments. According to Fact.MR report, the lithotripsy devices market is anticipated to accelerate at 4.3% CAGR during 2018-2026 to reach a value of US$ 1,095.2 MN by the end of 2026. In recent past, lithotripsy has become the most preferred way of treating kidney stones, owing to myriad advantages of lithotripsy devices, such as low cost, relative safety, negligible recovery time and positive results.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=3084

The Fact.MR report on lithotripsy devices market opines that the growing adoption of lithotripsy devices owing to their ability to treat all kinds of kidney stones with impressive success rates for ureteral stones without any considerable complications has been underpinning gains in lithotripsy devices market.

Surging Incidence of Urolithiasis to Boost Sales of Lithotripsy Devices

Urolithiasis is a widely prevalent urologic issue, which constitutes considerable burden on the healthcare system across the globe. According to Fact.MR report on lithotripsy devices market, apart from widespread prevalence, urolithiasis has been linked to an increased risk of end-stage renal failure, which has further accelerated the demand for lithotripsy devices. As per the U.S. National Institutes of Health, urolithiasis affects roughly 12% of the worldwide population once in lifetime. The report opines that the growing prevalence of kidney stones is likely to drive the growth of lithotripsy devices market during the forecast period.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=3084

The rapidly advancing technology and manifold extracorporeal shock wave lithotripsy procedures are anticipated to act as a main growth driver for lithotripsy devices market, as per Fact.MR study. Further, lithotripsy devices’ manufacturers are focusing on creating novel and cutting-edge lithotripsy devices, which is expected to fuel growth in global lithotripsy devices market during 2018-2026.

The Fact.MR report on lithotripsy devices opines that lithotripsy procedures are likely to become an outpatient procedure in the forthcoming years, witnessing a robust growth in ambulatory surgical center segment by end users. Though there are newer ways for the treatment of kidney stones, patients are increasingly opting for minimally invasive or non-invasive treatment as a viable method for kidney stones treatment.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/3084

Furthermore, as modern day lithotripters provide a wide range of settings to clinicians, medical practitioners get the liberty to adopt diverse combinations with various effects during the procedure. However, the prevalence of substitutes for kidney stones treatment is likely to dampen the growth of lithotripsy market during the foreseeable period. Additionally, adverse effects linked to the use lithotripsy, such as internal bleeding is another key factor likely to dampen the growth of lithotripsy devices market.

Europe to Dominate Lithotripsy Devices Market with Prevalence of Key Market Players

According to Fact.MR analysis of lithotripsy devices market, Europe is envisaged to dominate lithotripsy devices market and is projected to reach US$ 307.5 MN by the end of foreseeable period due to the presence of leading market players in the region.

Europe will be closely trialed by Asia-Pacific excluding China (APEC) lithotripsy devices market. APEC lithotripsy devices market is likely to account for second largest value share in lithotripsy devices market due to increasing burden of chronic diseases in tandem with the developing healthcare infrastructure in the region, apart from the growing initiatives to promote adoption of lithotripsy devices.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Bartter Syndrome Treatment Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2192/bartter-syndrome-treatment-market

Antibacterial Washcloth Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2190/antibacterial-washcloth-market

Acromegaly Treatment Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2191/acromegaly-treatment-market

About Us:

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Tags Lithotripsy Devices Market, Lithotripsy Devices Market Analysis, Lithotripsy Devices Market Demand, Lithotripsy Devices Market Estimate, Lithotripsy Devices Market Forecast, Lithotripsy Devices Market Insights, Lithotripsy Devices Market Scope, Lithotripsy Devices Market Share, Lithotripsy Devices Market Size, Lithotripsy Devices Market Statistics, Lithotripsy Devices Market Trends

Pharmaceutical

Biologics Drugs and PDE4 Inhibitors to Account for Major Chunk of Atopic Dermatitis Market Share Through 2027

Post author By administrator
Post date October 15, 2021
No Comments on Biologics Drugs and PDE4 Inhibitors to Account for Major Chunk of Atopic Dermatitis Market Share Through 2027

Dermatological disorders are increasing with each passing day. The World Health Organization estimates that more than 900 million people are suffering from skin ailments since 2017. Atopic dermatitis accounts for a major chunk of these illnesses, with more than 300 million people, mostly children, affected by it. Based on the aforementioned trends, the global atopic dermatitis drugs is expected to register astounding growth of 24% between 2020 and 2027.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4603

Research and development in manufacturing novel drugs, rising demand for biologics and product approvals are other factors augmenting market growth. On this premise, the atopic dermatitis market is poised to surpass a valuation of US$ 19 Bn by the end of the forecast period.

Key Takeaways of Global Atopic Dermatitis Drugs Market Study

Biologics Drugs is the leading segment by drug class. Projected CAGR for the same is pegged at a staggering CAGR of 32.1% during the forecast period. New product launches and increased adoption of Biologics drugs are key factors driving the growth of the segment.
PDE4 Inhibitors closely follow the biologics drugs segment, registering a whopping CAGR of 31.1%. Increased affordability of treatment and intensive research and development are expected to drive the growth of PDE4 Inhibitors.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=4603

Retail Pharmacies are expected to account for three-fourth of the market share for atopic dermatitis drugs. Increased number of retail pharmacies, easy availability of therapeutic drugs and convenience are some contributing factors.
North America shall retain its dominance in the atopic dermatitis drugs market. Adoption of advanced biologics drugs, adequate reimbursement coverage for pharmaceutical companies and greater market penetration of new players are some major growth stimulators. The region is set to expand at a CAGR of 27% during the forecast period.
Europe is the second most attractive market, accounting for around one-third of the global atopic dermatitis drugs market. This is due to increased awareness about the disease, favorable medical reimbursement policies and well-established healthcare facilities

Global Atopic Dermatitis Drugs Market Segmentation

Fact.MR has studied the global atopic dermatitis drugs market with detailed segmentation on the basis product type, application and key regions.

Drug Class	Corticosteroids PDE4 Inhibitors Biologics Skin Barrier Emollients CNI Immunosuppressants Others
Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies
Key Regions	North America Europe Asia Pacific Latin America Middle East & Africa

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4603

Development of Novel Drugs to Determine Market Competitiveness

Investments in development of novel pipeline drugs is expected to shape the global atopic dermatitis drugs market competitiveness. An example for this is the development of the biologics drug DUPIXNET ® by Sanofi Genzyme, which cures skin lesions and reduces itching. It does so by inhibiting secretions of interleukin-4 (IL-4) and interleukin-13 (IL-13) protein strains, responsible for type 2 skin inflammation. Likewise, Eucrisa (crisaborole), developed by Pfizer, Inc., consists of PDE4 Inhibitors to treat skin ailments like Eczema. It works by controlling the over-reactive parts of the PDE4 enzyme within skin cells to prevent inflammation.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

ENT Cameras Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2281/ent-cameras-market

Oral & Topical Anaesthetics Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2279/oral-topical-anaesthetics-market

About Us:

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Tags Atopic Dermatitis Market, Atopic Dermatitis Market Analysis, Atopic Dermatitis Market Demand, Atopic Dermatitis Market Estimate, Atopic Dermatitis Market Forecast, Atopic Dermatitis Market Insights, Atopic Dermatitis Market Scope, Atopic Dermatitis Market Share, Atopic Dermatitis Market Size, Atopic Dermatitis Market Statistics, Atopic Dermatitis Market Trends

Pharmaceutical

Sales of Beta Lactams to Bring in US$ 500 Million Revenue by 2026 end

Post author By administrator
Post date October 15, 2021
No Comments on Sales of Beta Lactams to Bring in US$ 500 Million Revenue by 2026 end

Pharyngitis also known as pharynx is inflammation of the back of the throat resulting in a sore throat. It may be bacterial or viral, the most common bacteria that infect human throat is Group A Streptococcus. Various market players are working on developing rapid diagnostic testing solutions for the fast detection of infection to provide treatment at an early stage. According to the medical professionals, around 50% of a sore throat or pharyngitis is caused by viral infection, while around 15-20% is caused by bacterial infection.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=361

Hence, throat lozenges are also being prescribed for people suffering from pharyngitis and it also offers temporary relief from cough and cold, which the most common cause of sore throat. As per Randomized Controlled Trial (RCT) published recently in Canadian Medical Association Journal, found that probiotics and xylitol chewing gum have no effect on a sore throat or pharyngitis symptoms. Hence, drug manufacturers are conducting research to develop new drugs to fight sore throat without causing any side-effects.

As per the report compiled by Fact.MR, the global pharyngitis market is expected to witness sluggish growth. The market is likely to register 3.4% CAGR during the forecast period 2017-2026. The global pharyngitis market is also estimated to reach US$ 1,679.0 million revenue by the end of 2026.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=361

Pharyngitis is the most common problem among people. It is mostly caused due to other illness such as flu, cold, or mononucleosis it results in sore throat. Most of the health providers diagnose pharyngitis with the help of rapid strep test. Medicines are given by doctor only after determining whether the infection is viral or bacterial. Hence, manufacturers of drugs are conducting research to develop more effective drugs to treat pharyngitis. Below are few insights on how the global pharyngitis market will perform in the coming years.

5 Forecast Highlights on Global Pharyngitis Market

Asia Pacific Excluding Japan (APEJ) is expected to remain dominant in the global pharyngitis market during the forecast period. Group A Streptococcus is a most common disease caused in settings of poverty, where transmission of an organism is possible due to the poor living condition. Hence, APEJ presents an opportunity for drug manufacturers. Moreover, the presence of key drug manufacturers in the region is also resulting in the growth of the market.
North America is also expected to witness growth in the coming years. As the cigarette smoking is very common among young adults and is significantly associated with sore throat. Moreover, there has been an increase in the cases of acute pharyngitis diagnosed in children in the U.S.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/361

Beta lactams is expected to be one of the highly preferred drug class in the global pharyngitis market. By the end of 2026, beta lactams is estimated to reach close to US$ 500 million revenue.
Retail pharmacies and drug stores are expected to witness the highest growth during the forecast period 2017-2026. Retail pharmacies and drug stores are estimated to exceed US$ 600 million revenue towards the end of 2026.
Oral drug delivery is expected to be the most preferred drug administration route as it is convenient and also costs the least. Accounting for more than half of the revenue share, oral drug delivery is estimated to exceed US$ 1,200 million revenue by the end of 2026.

Market Taxonomy

Drug Class	Beta Lactams Macrolides Cephalosporins Fluoroquinolones Tetracycline Other Products
Distribution Channel	Hospital Pharmacies Retail Pharmacies and Drug Stores Online Pharmacies
Mode of Delivery	Oral Intravenous Intramuscular Other Mode of Delivery

The report has also profiled leading players in the global market for pharyngitis, which will remain active through 2026. These include companies such as GlaxoSmithKline PLC, Pfizer Inc., Novartis AG, Zambon Group SpA, and BioStar Pharmaceuticals, Inc.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Bartter Syndrome Treatment Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2192/bartter-syndrome-treatment-market

Antibacterial Washcloth Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2190/antibacterial-washcloth-market

Acromegaly Treatment Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028- https://www.factmr.com/report/2191/acromegaly-treatment-market

About Us:

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Tags Pharyngitis Market, Pharyngitis Market Analysis, Pharyngitis Market Demand, Pharyngitis Market Estimate, Pharyngitis Market Forecast, Pharyngitis Market Insights, Pharyngitis Market Scope, Pharyngitis Market Share, Pharyngitis Market Size, Pharyngitis Market Statistics, Pharyngitis Market Trends